ECRONICON OPEN ACCESS

EC MICROBIOLOGY
Review Article

Effects of Lutein and Zeaxanthin in Diabetic Retinopathy

Turki Mohammed R Alqarni[1]*, Roula Hadyan M Al-Hadyan[2], Muruj Mohammed S Jumah[3], Aishah Nabil Azam[4], Tamadhor Ahmed Alghamdi[5], Bakri Sultan Mousa A[6], Shaza Omar H Alorabi[5], Tahany Faisal Farhan Alshammari[11], Layla Hassan H Jamjoom[5], Ghadeer Mohammed S Jumah[4], Najlaa Samran Almutairi[7], Lama Hassan Ali Saleh[8], Abdulwahab Salah A Almousa[9] and Razan Ahmed M Aljadrawi[10]

[1]Batterjee Medical College, Jeddah, Saudi Arabia

[2]Almaarefa Colleges, Riyadh, Saudi Arabia

[3]George Washington University, Washington, United States of America

[4]Taibah University, Medina, Saudi Arabia

[5]King Abdulaziz University, Jeddah, Saudi Arabia

[6]Prince Mohammad Bin Nasser Hospital, Jazan, Saudi Arabia

[7]Tabuk University, Tabuk, Saudi Arabia

[8]King Fahad Specialist Hospital, Tabuk, Saudi Arabia

[9]King Faisal University, Hofuf, Saudi Arabia

[10]Ibn Sina National College, Jeddah, Saudi Arabia

[11]Hail University, Hail, Saudi Arabia

***Corresponding Author**: Turki Mohammed R Alqarni, Batterjee Medical College, Jeddah, Saudi Arabia.

Received: August 18, 2017; **Published:** August 21, 2017

Abstract

Diabetic retinopathy (DR) is a standout amongst the most vital microvascular confusions of diabetes and remains the primary cause of blindness in the working-age people. The exact aetiopathogenesis of DR stays tricky regardless of significant advances in fundamental science and clinical research. Oxidative harm as one of the fundamental foundations for DR is progressively being perceived. In people, three hydroxycarotenoids, lutein (L), zeaxanthin (Z) and meso-zeaxanthin (MZ), aggregate at the focal retina (to the prohibition of all other dietary carotenoids), where they are collectively identified as macular pigment. These hydroxycarotenoids by nature of their biochemical structure and function help neutralise reactive oxygen species, and in this manner, avoid oxidative harm to the retina (biological antioxidants). Aside from their key antioxidant purpose, proof is developing that these carotenoids may likewise parade neuroprotective and anti-inflammatory function in the retina. Since the preparatory recognizable proof of hydroxycarotenoid in the human macula by Wald in the 1940s, there has been amazing advancement in our insight into the part of these carotenoids in advancing ocular health. Whereas the Age-Related Eye Disease Study 2 has recognized a clinical benefit for lutein and zeaxanthin supplements in patients with age-related macular deterioration, the part of these carotenoids in other retinal ailments conceivably connected to oxidative harm stays uncertain.

Keywords: *Diabetic Retinopathy; Lutein; Zeaxanthin; Hydroxycarotenoids*

Introduction

Diabetic retinopathy (DR) is the major cause of blindness between working-age persons around the world [1]. There are approximately 93 million people with DR worldwide, including 17 million with proliferative diabetic retinopathy and 28 million with vision intimidating diabetic retinopathy [2]. Generally, diabetic retinopathy was deliberated to be comparatively uncommon in middle-income

countries; on the other hand, there is a rising pervasiveness of diabetes in Asian countries, such as India and China, because of changes in the lifestyle (such as diet, physical activity, and pressure), economies and durability [3]. Diabetic retinopathy is the most particular microvascular entanglement of diabetes and is portrayed by early non-proliferative and late proliferative stage, the last stage described by development of new vessels in the retina. The proliferative phases of DR, together with diabetic macular oedema that can create at any stage, are the essential drivers of irreversible visual misfortune in people with diabetes (sight-threatening DR). People with Diabetic retinopathy additionally have higher danger of foundational vascular entanglements, including subclinical and clinical stroke, coronary illness, heart disappointment and nephropathy [4]. These macrovascular intricacies fundamentally influence the grimness and mortality related with diabetes and add to the regularly developing cost related with diabetes. Early discovery and rapid treatment remains the best quality level for improving visual deficiency because of DR. Despite the fact that the beginning and movement of DR is fundamentally connected with certain key hazard factors, for example, poor glycaemic control, longer length of diabetes, hypertension and dyslipidaemia, there is impressive variety in the consistency, example and quality of these hazard factors. There could likewise be included hereditary commitment in the advancement and movement of DR; in any case, distinguishing proof of vulnerable loci through competitor quality methodologies, linkage studies and extensive affiliation contemplates stay in their beginning periods. In addition, current treatment modalities for DR are restricted to laser photocoagulation and additionally intravitreal infusions of vascular endothelial development factor (VEGF) inhibitors/steroids however these modalities are intrusive, costly and should be rehashed at visit intervals [5]. Therefore, there is a requirement for new modalities for Diabetic retinopathy that is protection in nature and preferably can be actualized some time before unmistakable clinical signs improve.

Oxidative Damage in Diabetic retinopathy

Diabetic retinopathy is thought to be a multifactorial illness with the exact aetiopathogenesis being still unclear. Oxidative harm as one of the underlying reasons for DR is progressively being known. Oxidative damage arises due to an increase making of reactive oxygen species (ROS) concomitant with reduction in antioxidant defence system and is attributable to both the genesis as well as progress of Diabetic retinopathy. The retina is highly susceptible to oxidative damage as of several reasons:

- High content of polyunsaturated fatty acids in photoreceptor outer segment.
- High oxygen acceptance and glucose oxidation comparative to any other tissue.
- Continuous exposure to light.
- Profusion of photo sensitisers.

Indication is developing to recommend that oxidative damage happens in retinal vascular cells (capillary cells) besides non-vascular retinal cells (Müllers cells, bipolar, amacrine and photoreceptors) in early stages of diabetic retinopathy [6].

Increase Production of reactive oxygen species

The mitochondrial electron in our body transport chain of oxidative phosphorylation is the real site for cell generation of reactive oxygen species. As electron benefactors go through the buildings of this vehicle chain, around 5% of electrons specifically break to oxygen bringing about the development of superoxide free radicals. Under ordinary metabolic conditions, these radicals quickly diffuse into cytosol where they are disposed of by cancer prevention agent protection framework. In diabetes, because of supported hyperglycaemia, more glucose is accessible for oxidation and this enables more electron givers to go through the electron transport chain with noteworthy expanded generation of superoxide radicals. The current cancer prevention agent barrier framework can't adapt to expanded levels of these free radicals, in this manner bringing about oxidative harm to tissues.

The retinal mitochondria experiences oxidative harm because of overexpression of superoxide free radicals by the accompanying mechanisms [7]:

- Diminished movement of complex III of the electron transport chain.

- Harm to mitochondrial DNA bringing about traded off mitochondrial-DNA-encoded qualities,
- Compromised DNA repair framework
- Changed layer potential. In creature models, overexpression of mitochondrial superoxide radical causes mitochondrial brokenness and the advancement of diabetic retinopathy.

Harmed electron transport chain avoids successful exchange of electrons amid oxidative phosphorylation and, thus, produces more ROS bringing about positive criticism cycle where increment in ROS level prompts mitochondrial harm that in the end yields more ROS. Along these lines, an endless loop of free radical proceeds to self-propagate. Although mitochondria are major endogenous wellspring of ROS, ROS are additionally created in the cytosol by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and these cytosolic ROS harm the mitochondria in a dynamic manner [8].

Hyperglycaemia-incited overproduction of ROS actuates elective metabolic pathways by restraint of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) that outcomes in an expansion in its upstream glycolytic metabolite, glyceraldehyde-3-phosphate [9]. This metabolite, thus, initiates propelled glycation finished results (AGEs), protein kinase C and hexosamine pathway by means of expanding methylglyoxal, diacylglycerol and fructose-6-phosphate levels, respectively. It is essential to take note of that the procedure of AGEs development itself is related with ROS creation as side-effects, and hence, adds to oxidative harm (AGEs and oxidative anxiety can nourish into each other). A few lines of proof propose a nearby connection amongst AGEs and DR:

- AGEs are expanded in the retinal microvasculature from patients with diabetes [10].
- Serum levels of AGEs relate with the seriousness of Diabetic retinopathy [10].
- A positive relationship amongst's AGEs and the improvement and movement of DR,
- Cell-surface AGE-restricting receptor levels and polymorphisms in quality encoding for these receptors fill in as surrogate marker for Diabetic retinopathy.
- Adjustment of various other metabolic and useful anomalies related with Diabetic retinopathy, including internal blood-retinal boundary breakdown [11].

Also, restraint of GAPDH builds the level of glucose, which can additionally fuel into polyol pathway and expands the utilization of NADPH and NAD+ levels (cofactors essential in redox responses). Fructose created by polyol pathway can be phosphorylated to fructose-3-phosphate that expands AGE arrangement by means of filling in as a glycosylating agent. Expanded polyol pathway movement is seen in the retina from creature models of DR and from diabetic human benefactors with retinopathy [12]. The connection between polyol pathway and DR is additionally fortified by the relationship between the C allele polymorphism at 106-position (the promoter of aldose reductase quality AKR1B1) and Diabetic retinopathy. likewise, late proof showed that diabetes increments arginase action in the retina, which by diminishing arginine supply for nitric oxide synthase, lessens nitric oxide levels and increment superoxide free radical generation. Superoxide responds with nitric oxide, producing peroxynitrite, and expanded retinal levels of peroxynitrite has been involved in vascular and neural harm related with Diabetic retinopathy [13].

Decrease in Antioxidant Defence System

Diabetes is related with traded off cancer prevention agent guard framework that checks the impact of ROS. Glutathione (GSH) is an intense endogenous cancer prevention agent that is important for cell resistance against ROS. In diabetic retina, diminish in intracellular levels of GSH, because of consumption of NADPH and authoritative of AGEs to their receptors, is joined by attending increment in oxidized GSH [14]. GSH can be recovered from oxidized GSH; in any case, in diabetics, the chemicals for GSH redox cycle (GSH peroxidase and reductase) and for biosynthesis and corruption of GSH (γ-glutamyltranspeptidase and glutamate cysteine ligase) are compromised. Similarly, the exercises of Cu-Zn superoxide dismutase (SOD) and manganese SOD, mass scrounger of superoxide radicals, are diminished in the retina and its narrow cells of diabetics [15]. Glial cells regularly deliver a lot of GSH and hyperglycaemia-prompted consumption of GSH inside the glial cells brings about impeded glutamate metabolism [16]. This comes full circle in arrival of provocative substances

by glial cells that harm their nearby auxiliary association with blood vessels. These progressions may most likely be connected to an expanded vascular penetrability bringing about diabetic macular oedema. Furthermore, there is diminish in transcriptional action of atomic factor (erythroid-derived 2)- like 2, a redox delicate translation factor in Diabetic retinopathy, alongside diminish in the catalytic subunit of glutamate cysteine ligase additionally including oxidative weight the retina [17].

Lutein and Zeaxanthin

Lutein L, Zeaxanthin Z and meso-zeaxanthin (MZ) are the three hydroxycarotenoids that are specifically amassed in the primate macula to shape a yellow pigment known as macular pigment (MP). MP represents 20% - 30% of aggregate carotenoids in the human serum yet 80% - 90% of carotenoids in the human retina [18]. L and Z can't be orchestrated in the human body and is gotten from dietary admission of these carotenoids, for example, brilliantly hued products of the soil, including green verdant vegetables. There is a continuous open deliberation about the cause of MZ, however the general agreement appears that MZ is gotten from retinal L through an inadequately comprehended procedure of bioconversion as well as from particular nourishment sources, for example, certain types of palatable fish, shrimp and ocean turtles [19]. The anatomical area of MP has produced enthusiasm for the part of MP for vision and macular wellbeing. The hydroxycarotenoids constituting MP are exceedingly moved in the focal retina (the macula) and their focus diminishes almost 100-fold with expanding retinal eccentricity. At the macula, the proportion of L:Z:MZ is 1:1:1 while in the fringe retina, L prevails over Z and MZ by a 3:1:0 [20]. At the macula, each of the three hydroxycarotenoids exhibits a territorial strength. L is the overwhelming carotenoid in the fringe macula, Z in the mid fringe macula and MZ at the epicenter of the macula. Within the retina, these carotenoids have most elevated focus in the receptor axon layer and in the inward plexiform layers [21]. In people, estimation of MP is achievable in vivo with an extensive variety of systems that are ordinarily sorted into two noteworthy gatherings: psychophysical (requiring a reaction from the subject) and target (requiring negligible contribution from the subject) [22]. There is expanding proof that MP levels in the retina can be enlarged through expanded admission of dietary L and Z in sound and ailing retinas, proposing the likelihood that helpful intercession as dietary adjustment or healthful supplementation may balance the danger of infections related with a relative absence of MP [23]. Furthermore, incorporation of MZ in the carotenoid supplementation brings about more noteworthy increment in MP contrasted and supplements without this focal carotenoid [24].

Anti-inflammatory Function

DR is accepted to be a second rate perpetual provocative infection with subclinical aggravation in charge of a hefty portion of the vascular sores related with DR. ROS are viewed as a solid jolt for initiation of various star provocative pathways. What's more, a few intracellular flagging pathways downstream of irritation are related with oxidative harm. Developing proof recommends that L and Z may counteract advancement of DR by stifling ROS initiated by inflammation [25]. Li., *et al*. [26] examined the calming impacts of L in murine models and watched that there is diminished creation of star provocative components from Müller cells in the L-treated gathering when contrasted and control gathering. Correspondingly, Z organization averted diabetes-instigated increment in retinal VEGF levels, in this manner giving potential to avoid DR by controlling development factors. Increased levels of VEGF assume a vital part in ahead of schedule (expanded cell penetrability) and late stages (angiogenesis) of DR. Besides, L may prompt changes in articulation of aggravation related qualities and this perception has been shown in the retinal color epithelium (RPE). Bian., *et al*. [27] have demonstrated that cell reinforcements hinder increment in retinal redox-delicate atomic transcriptional factor-B (NF-κB, a transcriptional factor controlling the declaration of numerous genes involved with irritation) and along these lines may keep the advancement of DR.

Neuroprotective Function

Lutein may keep the improvement of Diabetic retinopathy by means of its neuroprotective impact; however the atomic reason for this impact stays obscure. It is trusted that degeneration of retinal neurons and glial cells happens before the improvement of clinical indications of Diabetic retinopathy, for example, microaneurysms. In reality, anomalous reactions of oscillatory possibilities in electroretinograms reflecting breaking down of inward retinal layers were seen in beginning periods of DR in exploratory creatures and also

humans [28]. Synaptophysin is a synaptic vesicle protein that is vital for neurotransmitter discharge and synaptic system movement. It is rich in the internal plexiform layer and assumes a key part in different neurodegenerative infections. In creature models with diabetes, supplementation with L was related with safeguarding of synaptophysin levels, alongside concealment of extracellular signal-regulated kinase (ERK) activation. ERK actuation prompts over the top debasement of synaptophysin through the ubiquitin-proteasome framework prompting diminished levels of synaptophysin. What's more, ERK actuation happens optional to angiotensin II-prompted ROS generation by means of angiotensin II sort 1 receptor and NAPH/NADPH oxidase recommending that L may go about as neuroprotective operator through its cell reinforcement work [29]. Protection of synaptophysin levels by L has extra ramifications past synaptic activity. Synaptic activity, that is, the neuronal electric jolts, actuates translocation of calcium particles and in addition articulation of a neuronal trophic factor (brain-derived neurotrophic factor (BDNF)). BDNF has been observed to be downregulated in diabetic retina like that related with various other neurodegenerative disorders. BDNF directs neurotransmitter discharge and neuronal movement and advances survival of internal retinal cells. Likewise, BDNF lessening may to some degree adds to the undeniable histological changes that in this way show up in the inward retina in Diabetic retinopathy. Diminishment in BDNF was lessened by L showing that this marvel was mostly caused by inordinate oxidative stress [30]. Of note, it stays to be resolved whether BDNF can be changed or debased by oxidative anxiety.

Antioxidant Function

L, Z and MZ by nature of their biochemical structure and meaning, help neutralise ROS and consequently avoid oxidative harm to the retina (biological antioxidant). Evidence exists to help a double component for the cancer prevention agent movement, to be specific singlet oxygen extinguishing and free radical rummaging. The extinguishing of ROS (receptive non-radical compound, for example, singlet oxygen) is principally by a physical instrument, in which the particle of a carotenoid acknowledges the excitation vitality from singlet oxygen. The additional vitality causes excitation of the carotenoid atom, bringing about the era of a "triplet" state, 3Car* [1O2*+1Car→3O2+3Car*] [31]. This triplet condition of carotenoid scatters vitality, innocuously, through rotational and vibrational connections, and unwinds into its ground state, 1Car [3Car*→1Car+Heat] [7]. Because this is a physical component, instead of a concoction response, the structure of the carotenoid particle stays unaltered. L, Z and MZ can rummage ROS (free radicals, for example, hydroxyl and peroxyl radicals) in two ways. In the first place, the free radical gets its missing electron by expelling an electron from the electron-rich particle of the carotenoids. Second, the free radical adds itself to the carotenoid atom to match its single electron, subsequently shaping a covalent bond. In either case, the electron-rich structure of the carotenoid atom pulls in free radicals, therefore saving the cell parts, for example, lipids, proteins and DNA from oxidative damage [32].

The polyene chain of the hydroxycarotenoids supply promptly accessible electrons that empower these carotenoids to rummage ROS and constrict oxidative damage. Z is twice as strong as L at searching ROS and this is credited to the expanded conjugated arrangement of Z when contrasted and L (double bonds in the carbon chain: Z = 11; L = 10) [33]. Moreover, MZ has been ended up being a more intense cancer prevention agent than Z when in conjunction with a Z-restricting protein. MZ varies from Z in the spatial introduction of the hydroxyl amass on the C3 chiral position (spatial introduction: Z = R; MZ = S), yet the conjugated framework in MZ is like Z. Of intrigue, a blend of L, Z, MZ *in vitro*, in a proportion of 1:1:1 has been appeared to extinguish more singlet oxygen than any of these individual carotenoids at a similar aggregate concentration. It is conceivable that when blended at this physiological proportion, these three carotenoids may shape particular totals, which could upgrade their capacity to extinguish singlet oxygen [33]. Moreover, L and Z embed themselves into the natural layers and have been appeared to expand the unbending nature of the lipid bilayers where they go about as 'atomic bolts' a direct result of their introduction inside the film. Z was found to embrace a generally opposite introduction to the plane of the layer, while L and its isomers take after the opposite and additionally parallel orientation. This impact of macular carotenoids on lipid film's basic and dynamic properties appears to diminish the susceptibility of lipid bilayers to oxidative degradation [34].

Conclusion

Lutein and Zeaxanthin have the prospective to prevent the improvement or delay the progression of Diabetic retinopathy in patients

with diabetes; nevertheless, there is paucity of existing data linking these unique carotenoids with Diabetic retinopathy among humans. In the future, sufficient research is required in this field before Lutein and Zeaxanthin establish their place in the clinical management of Diabetic retinopathy.

Bibliography

1. Klein BE. "Overview of epidemiologic studies of diabetic retinopathy". *Ophthalmic Epidemiology* 14.4 (2007): 179-183.
2. Yau JWY., *et al*. "Global prevalence and major risk factors of diabetic retinopathy". *Diabetes Care* 35.3 (2012): 556-564.
3. Ramachandran A., *et al*. "Trends in prevalence of diabetes in Asian countries". *World Journal of Diabetes* 3.6 (2012): 110-117.
4. Cheung N., *et al*. "Diabetic retinopathy". *Lancet* 376.9735 (2010): 124-136.
5. Osaadon P., *et al*. "A review of anti-VEGF agents for proliferative diabetic retinopathy". *Eye (London)* 28.5 (2014): 510-520.
6. Kern TS. "Interrelationships between the retinal neuroglia and vasculature in diabetes". *Diabetes and Metabolism* 38.3 (2014): 163-170.
7. Kowluru RA., *et al*. "Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy". *Progress in Retinal and Eye Research* 48 (2015): 40-61.
8. Frey RS., *et al*. "NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology". *Antioxidants and Redox Signaling* 11.4 (2009): 791-810.
9. Brownlee M. "The pathobiology of diabetic complications: a unifying mechanism". *Diabetes* 54.6 (2005): 1615-1625.
10. Aso Y., *et al*. "Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes". *Acta Diabetologica* 37.2 (2000): 87-92.
11. Genuth S., *et al*. "Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes". *Diabetes* 64.1 (2015): 266-278.
12. Dagher Z., *et al*. "Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy". *Diabetes* 53.9 (2004): 2404-2411.
13. Katakami N., *et al*. "Aldose reductase C-106T gene polymorphism is associated with diabetic retinopathy in Japanese patients with type 2 diabetes". *Diabetes Research and Clinical Practice* 92.3 (2011): e57-e60.
14. Kern TS., *et al*. "Abnormalities of retinal metabolism in diabetes or galactosemia. ATPases and glutathione". *Investigative Ophthalmology and Visual Science* 35.7 (1994): 2962-2967.
15. Yokoyama I., *et al*. "Prevention of free-radical induced apoptosis by induction of human recombinant Cu, Zn-SOD in pig endothelial cells". *Transplant International* 15.5 (2002): 220-225.
16. Leith E., *et al*. "Diabetes reduces glutamate oxidation and glutamine synthesis in the retina. Penn State Retina Research Group". Experimental Eye Research 70.6 (2000): 723-730.

17. Zhong Q., *et al*. "Transcription factor Nrf2-mediated antioxidant defense system in the development of diabetic retinopathy". *Investigative Ophthalmology and Visual Science* 54.6 (2013): 3941-3948.

18. Bone RA., *et al*. "Stereochemistry of the human macular carotenoids". *Investigative Ophthalmology and Visual Science* 34.6 (1993): 2033-2040.

19. Johnson E., *et al*. "Nutritional manipulation of primate retinas, III: effects of lutein and zeaxanthin supplementation on adipose tissue and retina of xanthophyll-free monkeys". *Investigative Ophthalmology and Visual Science* 46.2 (2005): 692-702.

20. Bone RA., *et al*. "Distribution of lutein and zeaxanthin stereoisomers in the human retina". *Experimental Eye Research* 64.2 (1997): 211-218.

21. Trieschmann M., *et al*. "Macular pigment in the human retina: histological evaluation of localization and distribution". *Eye (London)* 22.1 (2008): 132-137.

22. Howells O., *et al*. "Measuring macular pigment optical density in vivo: a review of techniques". *Graefe's Archive for Clinical and Experimental Ophthalmology* 249.3 (2011): 315-347.

23. The Age-Related Eye Disease Study 2 Research Group. "Lutein plus zeaxanthin and omega-3 fatty acids for age-related macular degeneration. The Age-Related Eye Disease Study 2 (AREDS 2) Randomized Clinical Trial". *Journal of the American Medical Association* 309.19 (2013): 2005-2015.

24. Akuffo KO., *et al*. "Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration". *Eye (London)* 29.7 (2015): 902-912.

25. Izumi-Nagai K., *et al*. "Macular pigment lutein is anti-inflammatory in preventing choroidal neovascularization". *Arteriosclerosis, Thrombosis, and Vascular Biology* 27.12 (2007): 2555-2562.

26. Li SY., *et al*. "Anti-inflammatory effects of lutein in retinal ischemic/hypoxic injury: *in vivo* and *in vitro* studies". *Investigative Ophthalmology and Visual Science* 53.10 (2012): 5976-5984.

27. Bian Q., *et al*. "Lutein and zeaxanthin supplementation reduces photooxidative damage and modulates the expression of inflammation-related genes in retinal pigment epithelial cells". *Free Radical Biology and Medicine* 53.6 (2012): 1298-1307.

28. Kizawa J., *et al*. "Changes of oscillatory potentials and photopic negative response in patients with early diabetic retinopathy". *Japanese Journal of Ophthalmology* 50.4 (2006): 367-373.

29. Sasaki M., *et al*. "Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes". *Diabetologia* 53.5 (2010): 971-979.

30. Binder DK and Scharfman HE. "Brain-derived neurotrophic factor". *Growth Factors* 22.3 (2004): 123-131.

31. Semba RD and Dagnelie G. "Are lutein and zeaxanthin conditionally essential nutrients for eye health?" *Medical Hypotheses* 61.4 (2003): 465-472.

32. Eperjesi F and Beatty S. "Nutrition and the Eye - A Practical Approach". Toronto: Elsevier (2005): 91-98.

33. Cantrell A., *et al*. "Singlet oxygen quenching by dietary carotenoids in a model membrane environment". *Archives of Biochemistry and Biophysics* 412.1 (2003): 47-54.

34. Sujak A., *et al*. "Lutein and zeaxanthin as protectors of lipid membranes against oxidative damage: the structural aspects". *Archives of Biochemistry and Biophysics* 371.2 (1999): 301-307.

Volume 11 Issue 1 August 2017